• Downloads
  • Contact Us
  • Directions
  • Deutsch Deutsch German de
  • English English English en
  • 简体中文 简体中文 Chinese (Simplified) zh-hans
Epitype GmbH
  • Products
  • About us
    • Management
    • Team
    • Research projects
    • Publications
    • Press
    • Jobs
  • Contact
    • Directions
    • Contact Us
  • News / Blog
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

Tag Archive for: MEDICA

Cancer diagnostics of the future thanks to highly informative biomarkers

Press Releases
The team of oncgnostics

oncgnostics at Medica 2022:

  • Cervical cancer screening test conquers China

  • Establishing early detection of head and neck tumours

  • First study results for screening test for vulva and vaginal cancer

  • At the joint stand of medways e.V. in Hall 15, Stand K10

Jena / Düsseldorf, November 08, 2022 – oncgnostics GmbH will present its technology, products and current study results at the largest trade fair in the medical sector. The company is an expert in molecular cancer diagnostics. Life-saving early detection is possible with the cancer tests developed by oncgnostics, which are based on patented biomarks.

Cancer diagnostics through biotechnology

DNA methylations form the basis of oncgnostics’ work. Specific changes in the DNA methylation pattern occur when cancer develops or is already present. The tests from oncgnostics detect these changes.

Innovation in cervical cancer screening

GynTect is the company’s first product. Used in cervical cancer diagnostics, the test is already being marketed in several European countries. In August of this year, it was approved in China, where it is marketed under exclusive licence. It is the first methylation test for triage of HPV-positive cases on the Chinese market.

The methylation test in cervical cancer screening

A cervical smear, as it is also taken for thin-layer cytology or the HPV test, is sufficient for the procedure. The test is a decision-making aid on how best to proceed after an abnormal screening result. GynTect not only allows to detect whether a tumour is already present, but also detects cervical lesions that may develop into cervical cancer – years in advance. Thus, risk assessment is greatly facilitated: on the one hand, unnecessary, premature operations can be avoided, and on the other hand, the chance for early and thus promising therapeutic measures can be increased.

ScreenYu Gyn is a further development of GynTect. The diagnostic test, which was CE IVD-approved in May this year, uses only one methylated DNA region, whereas GynTect detects six methylated DNA regions (biomarkers). This makes it particularly well suited for automation. With a simplified and automated test version, countries and regions can be served in which cervical cancer screening has hardly taken place so far. Most new cases of cervical cancer and most deaths due to the disease occur in these countries.

Establish early detection for head and neck tumours

Head and neck tumours are among the five most common cancers worldwide. They often develop unnoticed for a long time because the symptoms are usually unspecific for those affected. So far, no early diagnosis has been established for this group of tumours. oncgnostics is developing a test to change this. In this test, DNA methylation markers identified in cancer tissue and validated by oncgnostics, are detected in the patient’s saliva. The test will initially be used in post-surgical follow-up, as tumour markers that already appear in the primary tumour are also detectable in re-emerging tumours.

Vulva and vaginal cancer: early detection also overdue

Early detection of vulvar and vaginal cancer is also difficult due to non-specific symptoms or no symptoms at all. Initial studies have confirmed that a methylation test with the same biomarkers as for cervical cancer may also be useful here. oncgnostics is continuing to work on diagnostics for the early detection of vulvar and vaginal cancer on this basis.

_____________________________________________

About oncgnostics GmbH:

Jena-based oncgnostics GmbH specialises in the early detection of cancer. Its tests detect changes that are characteristic of the DNA of cancer cells. The company, founded in 2012, launched GynTect in 2015. In the context of early cervical cancer detection, the test clarifies whether cervical cancer or precancerous lesions are already present. oncgnostics GmbH is also conducting research into screening tests for other types of cancer. Detailed information is available at www.oncgnostics.com/en.

 

 

Free image material: www.oncgnostics.com/en/downloads

 

Contact:

oncgnostics GmbH

Löbstedter Str. 41

07749 Jena

Germany

Phone: +493641/5548550

pr(at)oncgnostics.com

www.oncgnostics.com

8. November 2022/by TowerPR
https://www.epitype.de/wp-content/uploads/2022/11/221011-ONC-Team_22_Webseite-scaled.jpg 974 2560 TowerPR https://www.epitype.de/wp-content/uploads/2025/09/epitype_website-logo-300x130.png TowerPR2022-11-08 11:50:512022-11-08 11:59:31Cancer diagnostics of the future thanks to highly informative biomarkers

MEDICA and COMPAMED 2019

Blog
MEDICA 2019oncgnostics GmbH

From 18 to 21 November we attended MEDICA 2019, in Düsseldorf. We were at the joint booth for the industry association medways e.V. in the world’s largest trade fair for the medical sector.

Record Number of Exhibitors and Visitors

This year the trade fair broke its own record once again with around 5,500 exhibitors and 121,000 visitors. About 170 different countries gathered at the No. 1 platform for international business. Many visitors came by oncgnostics’ booth to learn about our latest developments.

“For us, MEDICA is the most important trade fair of the year. This is where the industry comes together, where we make and maintain important contacts. As exhibitors, we are able to introduce ourselves, and we are very happy to use our own booth for meetings. At the same time, it is always worth taking a tour around the fair to get up to date,” says Dr Alfred Hansel, oncgnostics’ Managing Director, describing his impressions.

Pitch at COMPAMED

Dr. Peter Haug

Simultaneously to MEDICA, COMPAMED, the trade fair for medical suppliers, took place. Our Head of Business Development & Licensing, Dr Peter Haug, accepted the invitation of IVAM, the professional association for microtechnology, and gave a sales pitch at the High-tech for Medical Devices forum.

“Oncgnostics GmbH is not only a manufacturer of reliable and innovative devices for cancer diagnostics: It is also of interest as a development partner to other pharmaceutical and diagnostic companies that would like to develop reliable tests based on epigenetic markers for new indications with us. Moreover, thanks to our strategic partnership with GeneoDx, a subsidiary of the Chinese SINOPHARM Group, we are also able to offer high-volume orders,” summarises Dr Peter Haug.

6. December 2019/by Admin Spinger
https://www.epitype.de/wp-content/uploads/2019/11/20191119_124201_b.jpg 2269 3199 Admin Spinger https://www.epitype.de/wp-content/uploads/2025/09/epitype_website-logo-300x130.png Admin Spinger2019-12-06 13:07:012020-05-19 10:36:05MEDICA and COMPAMED 2019

Archive

Recent Posts

  • Worldwide unique test for cervical cancer as a gamechanger for the healthcare system
  • Jena Biotechnology Company Files for Insolvency
  • Bachelor thesis in biotechnology companies: From research to diagnostics 

Epitype GmbH

The Epitype GmbH, a spin-off of the University Hospital Jena, is a company working on molecular diagnostics with main focus on the development of in-vitro diagnostics based on epigenetic biomarkers.

Epitype GmbH is working according to ISO 13485 standards in research, development, production and management.

Recent Posts

  • Worldwide unique test for cervical cancer as a gamechanger for the healthcare system
  • Jena Biotechnology Company Files for Insolvency
  • Bachelor thesis in biotechnology companies: From research to diagnostics 

Contact

Epitype GmbH
Löbstedter Str. 41
07749 Jena
Germany

Phone: +49 (0)3641 5548500

Email: contact[at]epitype.de
Internet: www.epitype.de

© 2015 - 2025 Epitype GmbH Jena Germany
  • Start
  • Imprint
  • Contact Us
  • Privacy policy
Scroll to top

Cookies help us deliver our services. By using our services, you agree to our use of cookies.

Learn moreI accept

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy policy
Einstellungen akzeptierenVerberge nur die Benachrichtigung
Epitype GmbH
Manage Consent

To provide you with the best possible experience, we use technologies such as cookies to store and/or access device information. If you consent to these technologies, we may process data such as browsing behavior or unique identifiers on this website. If you do not give your consent or withdraw it, certain features and functions may be affected.

Functional Always active
Technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service expressly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a message via an electronic communications network.
Preferences
Technical storage or access is necessary for the legitimate purpose of storing preferences that have not been requested by the subscriber or user.
Statistics
Technical storage or access carried out solely for statistical purposes. Technical storage or access used exclusively for anonymous statistical purposes. Without a court order, the voluntary consent of your internet service provider or additional records from third parties, the information stored or accessed for this purpose cannot, as a rule, be used on its own to identify you.
Marketing
Technical storage or access is required to create user profiles, to send advertising, or to track the user on a website or across multiple websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View settings
  • {title}
  • {title}
  • {title}